Alpiropride

Alpiropride
Clinical data
Trade names	Revistel, Rivistel, or Rivestel
Other names	Iristel; RIV-2093; RIV2093; RIV 2093; Riv 2093; Riv-2093; Riv2093
Drug class	Dopamine D2 receptor antagonist; Antihypertensive agent; Antimigraine agent
Identifiers
	IUPAC name 4-amino-2-methoxy-5-(methylsulfamoyl)-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]benzamide;
CAS Number	81982-32-3;
PubChem CID	71253;
ChemSpider	64384;
UNII	1768UW0XS1;
ChEBI	CHEBI:135599;
ChEMBL	ChEMBL2104024;
CompTox Dashboard (EPA)	DTXSID30868635 ;
ECHA InfoCard	100.072.585
Chemical and physical data
Formula	C17H26N4O4S
Molar mass	382.48 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CNS(=O)(=O)C1=C(C=C(C(=C1)C(=O)NCC2CCCN2CC=C)OC)N;
	InChI InChI=1S/C17H26N4O4S/c1-4-7-21-8-5-6-12(21)11-20-17(22)13-9-16(26(23,24)19-2)14(18)10-15(13)25-3/h4,9-10,12,19H,1,5-8,11,18H2,2-3H3,(H,20,22); Key:QRQMZZNDJGHPHZ-UHFFFAOYSA-N;

Alpiropride (INNTooltip International Nonproprietary Name; brand name Revistel, Rivistel, or Rivestel) is a dopamine D₂ receptor antagonist of the benzamide group related to sulpiride.^[1]^[2]^[3]^[4]^[5] It is described as an antihypertensive agent and has been marketed for use as an antimigraine medication in Portugal.^[1]^[4]^[2] The drug was first described by 1980^[1] and was introduced for medical use by 1989.^[4] It remained marketed in Portugal as late as 2000.^[2]

References

^ ^a ^b ^c Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 33. ISBN 978-1-4757-2085-3. Retrieved 24 October 2024.
^ ^a ^b ^c Schweizerischer Apotheker-Verein (2000). Index Nominum 2000: International Drug Directory. Medpharm Scientific Publishers. p. 31. ISBN 978-3-88763-075-1. Retrieved 24 October 2024.
^ Milne GW (2018). Drugs: Synonyms and Properties. Routledge Revivals. Taylor & Francis. p. 358. ISBN 978-1-351-78990-5. Retrieved 24 October 2024.
^ ^a ^b ^c Ong HH, Allen RC (1989). "Chapter 31. To Market, To Market -1988". Annual Reports in Medicinal Chemistry. Vol. 24. Elsevier. pp. 295–315. doi:10.1016/s0065-7743(08)60553-9. ISBN 978-0-12-040524-4. ISSN 0065-7743.
^ Ren S, Lien LL, Lien EJ (August 1997). "Molecular modeling and structural analysis of benzamide derivatives with and without extrapyramidal syndrome side effects.". Current Medicinal Chemistry. Vol. 4. Bentham Science Publishers. pp. 271-278 (275). Retrieved 24 October 2024.

This analgesic-related article is a stub. You can help Wikipedia by expanding it.